<DOC>
	<DOCNO>NCT00113607</DOCNO>
	<brief_summary>The purpose study compare progression-free survival ( PFS ) combination trabectedin + DOXIL DOXIL monotherapy patient ovarian cancer .</brief_summary>
	<brief_title>An Efficacy Safety Study Yondelis ( Trabectedin ) Patients With Advanced Relapsed Ovarian Cancer</brief_title>
	<detailed_description>This multicenter , open-label ( people know identity intervention ) , randomize ( study medication assign chance ) , Phase 3 study compare combination trabectedin + DOXIL DOXIL monotherapy patient advanced ovarian cancer ( previously treat first-line platinum-based chemotherapy regimen fail ) . Approximately 650 patient randomly assign 1 treatment arm ( DOXIL DOXIL + trabectedin ) 2 year . At time randomization , patient stratify basis platinum sensitivity disease ( sensitive resistant ) baseline Eastern Cooperative Oncology Group performance status score ( 0 1 2 . Safety evaluate basis adverse event , clinical laboratory test , physical examination , vital sign assessment cardiovascular safety assessment . An interim analysis overall survival perform conjunction progression-free survival analysis study . Treatment continue disease progression occur patient experience confirmed complete response least 2 cycle . Continuation treatment select individual patient beyond study end date allow investigator determine patient benefiting treatment , eligible receive therapy , consent treatment . If disease progression occur treatment termination , disease assessment continue every 8 week evidence disease progression death , clinical data cutoff date , start first subsequent anticancer therapy , whichever early .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically proven epithelial ovarian cancer , epithelial fallopian tube cancer , primary peritoneal cancer Prior treatment 1 platinum base chemotherapy regimen Eastern Cooperative Oncology Group status 2 Progression 6 month start initial chemotherapy treatment Treatment 1 prior chemotherapy regimen Progression within 6 month start initial chemotherapy Prior exposure anthracyclines Unwilling unable central venous catheter Known clinically relevant central nervous system metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>Advanced Relapsed Ovarian Cancer</keyword>
	<keyword>DOXIL</keyword>
	<keyword>CAELYX</keyword>
</DOC>